Clinical

David Lieberman, MD, PhD, describes Rett syndrome, including the various stages, incidence, and potential causes of this disease.

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations.

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.

A new review has found that increased incidence of chronic kidney disease (CKD) may be seen among patients with nonalcoholic fatty liver disease.

In a sign that value-based care is here to stay, some practices that did not participate in the Oncology Care Model (OCM) have applied for the Enhancing Oncology Model (EOM).

Stemming from recent data on a potential link between major depressive disorder (MDD) and inflammation, research is starting to turn toward alternatives that can treat the disease through anti-inflammatory effects, including ketamine, cannabinoids, and psychedelics.

The Center for Medicare and Medicaid Innovation (CMMI) was a strong collaborator during the Oncology Care Mode (OCM), but the timing of the Enhancing Oncology Model came as a surprise.

Dr Cleary outlines strategies to individualize care for patients diagnosed with upper GI and esophageal cancer.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, provide insights regarding gastroesophageal treatment decisions when FDA labels don’t reflect clinical practice guidelines.

Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Expert panelists explore prevalence and disparities of MDD across patient populations.

Researchers found that different factors can negatively impact the Dermatology Life Quality Index scores for adults and adolescents with acne.

A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.

The new report is based on real-world data from a patient registry and shows some patients even regain motor function under treatment with nusinersen for spinal muscular atrophy (SMA).

Detailing findings from the secondary end points of the FIREFISH trial at 24 months, the researchers found that risdiplam treatment was associated with continued improvements in motor function and the achievement of development motor milestones.

Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.

The findings mean that scarring in the esophagus as a result of eosinophilic esophagitis (EoE) can be found earlier, allowing for more targeted intervention.

There are currently 3 FDA-approved therapies to treat cholangiocarcinoma with FGFR2 fusion or rearrangement, but these therapies face the development of resistance. Studies are underway to identify ways to overcome this resistance.

Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the Faculty of Medicine, Imperial College London, discussed how the potential teratogenic effects of novel therapies being investigated for lupus nephritis can impede clinical trial recruitment for women of childbearing age.

Compared with patients who have influenza infection, people infected with SARS-CoV-2 have a higher risk of epilepsy and seizures, according to a new study.

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement.

Different dietary approaches were able to improve the state of health in patients with type 2 diabetes (T2D), with very-low-calorie ketogenic diets demonstrating better results on gut microbiota profile.

A new study has found that a drop in serum inorganic phosphate (iP) was an early predictor of severe cytokine release syndrome (CRS), suggesting that monitoring serum iP levels could help promote safer management of the most common toxicity associated with chimeric antigen receptor (CAR) T-cell therapy.

Jorge Larranaga, MD, provides his opinion regarding the criticality of urgency in LN treatment.